ALZN

$1.46+$0.02 (+1.39%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$6.9M

5M shares

52-week range

$0.84 – $2.68

34% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-4723.54

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$32M	—	$-2.60	$-2.60–$-2.60	—	1
2028	$133M	+320.6%	$-3.04	$-3.04–$-3.04	—	1
2029	$32M	-75.7%	$-0.86	$-0.86–$-0.86	—	1
2030	$136M	+322.6%	$6.99	$6.99–$6.99	0.2×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ALZNAlzamend Neuro Inc	$1.46	+2.10%	$6M	—
ACXPAcurx Pharmaceuticals, Inc.	$1.48	-3.90%	$6M	—
ADILAdial Pharmaceuticals, Inc.	$4.39	+1.86%	$4M	—
APREAprea Therapeutics, Inc.	$0.67	-1.76%	$8M	—
BCDABioCardia, Inc.	$0.93	+5.56%	$14M	—
CDIOCardio Diagnostics Holdings, Inc.	$2.01	-6.94%	$6M	—

Source: Financial Modeling Prep · peers by sector/industry

Alzamend Neuro, Inc. Common Stock

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

www.alzamend.com

Employees: 6
IPO / List date: Jun 15, 2021
HQ: ATLANTA, GA

Held by traders on TradeandTell

No one on the platform currently holds ALZN.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ALZN as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2025-05-12	1-for-9reverse
2024-07-16	1-for-10reverse
2023-10-31	1-for-15reverse

Recent trades on TradeandTell

No one on the platform has traded ALZN yet.

$ALZN chatter on StockTwits

Mike Teal@hiwattBullish9h
$ALZN Well it's been one year since the Harvard paper on lithium in the brain has been published. Like this Neurologist in the video says, look for clinical trials of low dose lithium salts. One year later and only one company has completed a lithium brain trial and only one company has started a new lithium brain study, Alzn. Even Harvard has not started or posted a lithium study on clinical trials, and John Hopkins has posted a lithium study on clinical trials, but has not started recruiting yet. Even when Alzn reported positive results on their lithium in the brain study on tpo of all the euphoria of the Harvard Nature paper, the stock still sold off. I guess Rodney Dangerfield was right, no respect. https://www.instagram.com/reel/DNOzLU5Sqn2/?hl=en
View on StockTwits ↗
Aura@ExploringTradesBullish15h
Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $HCTI $ALZN XC
View on StockTwits ↗
Nick@H3D3RABullish3d
$ALZN
View on StockTwits ↗
Mike Teal@hiwatt6d
$ALZN WOW, Institutional ownership just just to over 30% with the additional of KMT Wealth Management. They have bought 1, 329,100 shares, which is over 25% of the float.
View on StockTwits ↗
Chrissie@Scrood_the_PoochAug 6
$GPUS @AntoineChigurh I just don't understand IceIceBaby's @WC25 issue with us dropping some cash for this noble cause. We still have plenty of room left on the $350M ATM, and we shouldn't have a problem doing another if it runs out. And we have such a good track record with $ALZN and are ATM partner. As they said in the call- running an ATM at 0.12 is not easy, why not throw are Spartan expert partners a bone? https://altswire.com/finra-charges-spartan-capital-ceo-and-cco-with-fraud-tied-to-private-placements-and-ipo/
View on StockTwits ↗
WC25B (The Thundering Whale)@WC25BullishAug 6
$GPUS @Ault Mr. Ault, good morning. Why did Hyperscale Data Inc just indirectly (through Ault Lending LLC) do a Purchase Agreement (Cash BAILOUT infusion) with Alzamend Neuro Inc $ALZN for an initial $7.5 Million worth of their new Series D Convertible Preferred Stock, with another $2.5 Million due ten days after the registration statement is effective, and the remaining $15 Million to be purchased in equal tranches over the next 15 months...none of which even have a Dividend attached!? Ault Lending LLC is owned by Ault Capital Group Inc, which is a wholly owned subsidiary of Hyperscale Data Inc. By potentially later this month alone, Ault Lending LLC will have taken a roughly 68% stake in ALZN once the new (convertible adjusted) 10,335,000 shares are added to the current est outstanding amount of 4.79 Million shares 'should it be authorized to convert all-at-once'...potentially climbing later to 84% ownership once the full $25 Million cash infusion is accounted for (cont'd)
View on StockTwits ↗
Mike Teal@hiwattAug 5
$ALZN Stock options acquired by CEO, 450,000 shares. https://d1io3yog0oux5.cloudfront.net/alzamend/sec/0001214659-26-009586/0001214659-26-009586.pdf
View on StockTwits ↗
Aura@ExploringTradesAug 4
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $ALZN $BBAI DND
View on StockTwits ↗
Aura@ExploringTradesAug 4
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $JAGX $HCTI $ALZN $BBAI su
View on StockTwits ↗
Mike Teal@hiwattAug 4
$ALZN This funding, along with stock trading above a dollar and marketcap above $5M, pretty much takes the reverse split off the table.
View on StockTwits ↗
Mike Teal@hiwattAug 4
$ALZN THe Lawsuit between Alzn vs Biorasi continues today. Biorasi was the CRO that apparently botched the AL002 clinical trial. From what I can gather a judge threw out one of the claims, but is allowing Alzn to continue on for breach on contract on the other 5 claims. https://cases.justia.com/federal/district-courts/florida/flsdce/1:2025cv20481/683068/106/0.pdf?ts=1769854003
View on StockTwits ↗
Aura@ExploringTradesAug 3
ave you seen the Ebola outbreak news this weekend?? 🤯 Make sure to put VRAX onto your watchlist 💎 Ticker VRAX is one of the tiniest float bio-techs that great cash position and Peptides against Ebola! I accumulated a huge amount of shares because of the recent Ebola outbreak. Numbers are rising concerningly fast. The right PR and it could see a big squeeze like the last time we saw an outbreak! $HCTI $ALZN Little vol today
View on StockTwits ↗
Mike Teal@hiwattBullishAug 3
$ALZN $$$.7.5M--https://ir.alzamend.com/sec-filings/all-sec-filings/content/0001214659-26-009469/0001214659-26-009469.pdf
View on StockTwits ↗
Mike Teal@hiwattBullishJul 29
$ALZN https://www.tipranks.com/news/company-announcements/alzamend-neuros-new-lithium-study-puts-al001-in-the-bipolar-disorder-spotlight
View on StockTwits ↗
Mike Teal@hiwattJul 28
$ALZN Noticed Alzn updated their clinical trial page today to say they started the BP study on 5-11. What I don't get is last year they did a PR 10 days after study started to announce first enrolled and 10 day after that another PR to announce first dosed. The stock went up 75% on the second PR. It has been 47 days since trial started and no PR. The good news is they didn't change study completion date and it's still set for 12-26 for now. They also did an 8K in March to announce delisting deadline. Apparently they got an extension but didn't bother to do an 8k to update shareholders, rather just put it in the 10K last week. I realize they operate on a shoestring budget, but can't the investor relations guy do a PR?
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.